期刊文献+

HPLC-MS/MS测定人血浆中羧甲司坦的浓度及其生物等效性研究 被引量:2

HPLC-MS/MS method for the determination of carbocisteine in human plasma and its bioequivalence
下载PDF
导出
摘要 目的建立HPLC-MS/MS方法测定人血浆中的羧甲司坦体内浓度,用于人体生物等效性分析。方法以直接沉淀法处理血浆,色谱柱为XTerra MS C18柱(150mm×2.1mm,5μm);流动相为甲醇-20mmol.L-1甲酸铵(含0.5%甲酸)(75∶25,v/v);流速为0.3mL.min-1;柱温为40℃。采用电喷雾离子源(ESI)负离子模式,用多反应监测模式(MRM)进行定量分析。结果羧甲司坦线性范围为0.210 9~54μg.mL-1,定量下限为0.210 9μg.mL-1,绝对回收率>80%,日内和日间RSD均<15%。结论此方法能够简便、高效、快速和灵敏的检测健康志愿者血浆中的羧甲司坦,可用于羧甲司坦药物代谢动力学及生物等效性研究。 Objective To establish a liquid chromatography-electrospray ionization tandem mass spectrum(HPLC-ESI-MS/MS) method to determine the carbocisteine in human plasma.Methods The XTerra MS C18(150 mm×2.1 mm,5 μm) column was used.The mobile phase was composed of 20 mmol·L-1 ammonium formate with 0.5% formic acid-methanol(25∶75,v/v),the flow rate was 0.3 mL·min-1,and the column temperature was 40 ℃.The ionization was optimized with ESI(-) and selectivity was enhanced with tandem mass spectrometric analysis via MRM functions,m/z 178.0→90.9 for carbocisteine and m/z 122→78.0 for the internal standard.Results The calibration curve was linear at 0.210 9-54 μg·mL-1(r= 0.998)for arbocisteine.The absolute recovery was more than 80%.The inter-day and intra-day RSDs were all less than 15%.Conclusion The method is simple,rapid,efficient,sensitive and suitable for the content determination of carbocisteine in the plasma of healthy volunteers,which can be used in the pharmacokinetics and bioequivalence research of carbocisteine.
出处 《中南药学》 CAS 2012年第2期114-117,共4页 Central South Pharmacy
关键词 液质联用 羧甲司坦 药物代谢动力学 生物等效性 HPLC-MS/MS carbocisteine pharmacokinetics bioequivalence
  • 相关文献

参考文献6

二级参考文献16

  • 1毕惠嫦,钟国平,汤铮,黄民.高效液相色谱法测定人血浆中羧甲司坦浓度[J].中国医院药学杂志,2005,25(9):828-830. 被引量:6
  • 2邓冲,李锋武,赵新锋,赵欣,祝忠民,郑晓晖.HPLC-FLD法测定人血浆中羧甲司坦的血药浓度[J].中国药业,2005,14(10):67-68. 被引量:3
  • 3李锐,骆海春,路雪芳.高效液相色谱法测定羧甲司坦片的含量[J].中国药师,2006,9(6):505-507. 被引量:4
  • 4陈秀琳.HPLC法测定氯霉素地塞米松搽剂的含量[J].中国药品标准,2006,7(5):49-50. 被引量:6
  • 5U.S. Department of health and human services, food and drug administration, center for drug evaluation and research (CD ER). Guidance for industry bioanalytical method validation [S/OL]. May:2001. http ://www. fda. gov/cder/guidance/index, htm.
  • 6De-Schutter JA,Vander WG,Vanden-Bossche W,et al. Determination of S-carboxymethylcysteine in serum by reversed-phase ionpair liquid chromatography with column switching following precolumn derivatization with o-phthalaldehyde[J]. J Chromatogr,1988,428(2): 301-310.
  • 7Staffeldt B,Brockmoller J,Roots I. Determination of S-carboxymethyl-L-cysteine and some of its metabolites in urine and serum by high-performance liquid chromatography using fluorescent precolumn labeling[J]. J Chromatogr, 1991,571 (1-2) : 133- 147.
  • 8Bron J. High pressure liquid chromatographic determination of carbocisteine in human plasma and urine[J]. Pharm Weekbl Sci,1986,8(2) : 134-138.
  • 9.中国药典:二部[S].,2005.附录197,附录7.
  • 10Wendy Gregory L, Oliver James FW, Jeffrey Idle R, et al. Carbocisteine polymorphism and disease. Lancet, 1992,339 (8793) :616

共引文献10

同被引文献25

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部